We are live on ! Find out more
PCRX icon

Pacira BioSciences

214 hedge funds and large institutions have $3.29B invested in Pacira BioSciences in 2015 Q4 according to their latest regulatory filings, with 62 funds opening new positions, 70 increasing their positions, 66 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

170% more first-time investments, than exits

New positions opened: 62 | Existing positions closed: 23

120% more funds holding in top 10

Funds holding in top 10: 511 (+6)

87% more capital invested

Capital invested by funds: $1.76B → $3.29B (+$1.53B)

21% more funds holding

Funds holding: 177214 (+37)

6% more repeat investments, than reductions

Existing positions increased: 70 | Existing positions reduced: 66

39% less call options, than puts

Call options by funds: $29M | Put options by funds: $47.5M

Holders
214
Holders Change
+37
Holders Change %
+20.9%
% of All Funds
5.61%
Holding in Top 10
11
Holding in Top 10 Change
+6
Holding in Top 10 Change %
+120%
% of All Funds
0.29%
New
62
Increased
70
Reduced
66
Closed
23
Calls
$29M
Puts
$47.5M
Net Calls
-$18.5M
Net Calls Change
-$18.2M
Name Holding Trade Value Shares
Change
Change in
Stake
T. Rowe Price Associates
1
T. Rowe Price Associates
Maryland
$310M +$7.19M +126,925 +3%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$301M +$53.1M +938,039 +31%
Vanguard Group
3
Vanguard Group
Pennsylvania
$190M +$4.14M +73,068 +3%
VAM
4
Visium Asset Management
New York
$176M -$37.4M -660,374 -22%
GGHC
5
Gilder Gagnon Howe & Co
New York
$170M +$2.88M +50,865 +2%
MCM
6
Marsico Capital Management
Colorado
$121M -$50.4M -889,841 -36%
BFA
7
BlackRock Fund Advisors
California
$120M -$5.37M -94,879 -6%
HCM
8
Hoplite Capital Management
New York
$94.2M -$11M -194,608 -14%
ClearBridge Investments
9
ClearBridge Investments
New York
$84.3M +$15.5M +273,458 +33%
State Street
10
State Street
Massachusetts
$81.6M -$1.48M -26,081 -2%
DCM
11
Daruma Capital Management
New York
$72.8M -$5.31M -93,729 -9%
Jennison Associates
12
Jennison Associates
New York
$72.3M -$673K -11,889 -1%
BIT
13
BlackRock Institutional Trust
California
$69.3M +$895K +15,798 +2%
Invesco
14
Invesco
Georgia
$67.7M -$1.82M -32,105 -4%
FAM
15
Fred Alger Management
New York
$59.7M +$32.2M +569,206 +273%
ORI
16
Oak Ridge Investments
Illinois
$59.7M -$669K -11,816 -1%
SI
17
Standard Investments
New York
$56.8M +$1.7M +30,000 +4%
CCI
18
Columbus Circle Investors
$56.7M +$41.8M +738,716 New
JHIU
19
Janus Henderson Investors US
Colorado
$51.5M -$13.5M -238,471 -26%
Westfield Capital Management
20
Westfield Capital Management
Massachusetts
$51.4M -$40.7M -719,604 -52%
Goldman Sachs
21
Goldman Sachs
New York
$46.2M -$27.7M -489,587 -45%
Lord, Abbett & Co
22
Lord, Abbett & Co
New Jersey
$43.8M +$32.3M +569,913 New
Northern Trust
23
Northern Trust
Illinois
$41.7M +$2.16M +38,215 +8%
SIMG
24
Stephens Investment Management Group
Texas
$41.5M +$2.78M +49,018 +10%
SCM
25
Sarissa Capital Management
Connecticut
$40.9M +$8.62M +152,200 +40%

PCRX Hedge Fund Activity: Q4 2015 in Review

214 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q4 2015, worth a combined $3.29B — up 87% from $1.76B a quarter earlier.

Buyers outnumbered sellers: 62 funds opened new PCRX positions and 23 closed out — a net gain of 39 holders — while 70 added to existing stakes and 66 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $53.1M. The largest seller was Ameriprise, cutting an estimated $52.9M.

  • 214 institutional investors held Pacira BioSciences (PCRX) as of Q4 2015, up from 177 in Q3 2015.
  • Funds reported $3.29B of Pacira BioSciences stock for Q4 2015, up 87% quarter-over-quarter.
  • 62 funds opened new Pacira BioSciences positions in Q4 2015 and 23 closed out, a net change of +39 holders.
  • The largest Pacira BioSciences buyer in Q4 2015 was Fidelity Investments, an estimated $53.1M added.
  • The largest Pacira BioSciences seller in Q4 2015 was Ameriprise, an estimated $52.9M sold.

Based on aggregated 13F filings for Q4 2015.